RE:Excellent analysis Canada FanWhen ONCY was planning to use pelo as a monotherapy, and ran the head and neck trial, they had results that were OK but not stellar. The FDA told them they had to split their samples into two groups and should rethink their strategy as a monotherapy. Thye also had various old trials (panc etc) that provided information over time showing, wonder of wonders, after about 6-9 months into the trial, that if people had not already died they started living longer. That was the immune response. That helped change the company's mind about its role and what the virus was really good for in terms of cancer treatment. It is, in effect, a wonderful agent to excite and stimulate the immune system.
Since then, they have completely redesigned their approach. We are within months of some kind of partnership IMHO.
The company has had to deal with the overhang of its previous vision as a monotherapy. Also being from Canada, and a small company, pursuing an oddball strategy, has been the knock on the company for a long time. Perceptions stick around.